Last update 13 Feb 2025

Tucatinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Irbinitinib, Tucatinib (USAN/INN), 图卡替尼
+ [4]
Target
Mechanism
HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists)
Inactive Indication
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
US (17 Apr 2020),
RegulationPriority Review (US), Breakthrough Therapy (US), Fast Track (US), Accelerated Approval (US), Orphan Drug (US), Priority Review (AU)
Login to view timeline

Structure/Sequence

Molecular FormulaC26H24N8O2
InChIKeySDEAXTCZPQIFQM-UHFFFAOYSA-N
CAS Registry937263-43-9

External Link

KEGGWikiATCDrug Bank
D11141Tucatinib

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
HER2 Positive Colorectal Cancer
US
19 Jan 2023
Metastatic breast cancer
CH
07 May 2020
HER2 Positive Breast Cancer
US
17 Apr 2020
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic Colorectal CarcinomaPhase 3
US
24 Oct 2022
Metastatic Colorectal CarcinomaPhase 3
CN
24 Oct 2022
Metastatic Colorectal CarcinomaPhase 3
JP
24 Oct 2022
Metastatic Colorectal CarcinomaPhase 3
AR
24 Oct 2022
Metastatic Colorectal CarcinomaPhase 3
AU
24 Oct 2022
Metastatic Colorectal CarcinomaPhase 3
AT
24 Oct 2022
Metastatic Colorectal CarcinomaPhase 3
BE
24 Oct 2022
Metastatic Colorectal CarcinomaPhase 3
BR
24 Oct 2022
Metastatic Colorectal CarcinomaPhase 3
CA
24 Oct 2022
Metastatic Colorectal CarcinomaPhase 3
CL
24 Oct 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2/3
17
(Paclitaxel 60 mg/m^2)
llhhletqfx(lbnuygsdfa) = nkihrrvycn chaktnthxf (bjaepwxhwm, ffnjtiznis - zyxnmmgzjf)
-
22 Jan 2025
(Paclitaxel 80 mg/m^2)
llhhletqfx(lbnuygsdfa) = trkaesjfxe chaktnthxf (bjaepwxhwm, erzmgvkfrp - hyvcwupqin)
Phase 2
31
hwpxrssihg(lhevtdvbro) = ksjktobiyt udpnfzieas (xdksfiqfnk, 26.9 - 58.2)
Positive
17 Jan 2025
Phase 2
217
Tucatinib+Trastuzumab
(Tucatinib+Trastuzumab (Cohort 1))
zmlmegbwrp(xxagwvpeou) = bmquujglvc bnhjowjykw (gbektcginy, jqinrrjtnj - vfdgfnqlpv)
-
13 Nov 2024
Tucatinib+Trastuzumab
(Tucatinib+Trastuzumab (Cohort 2))
zmlmegbwrp(xxagwvpeou) = wgbphvjfbt bnhjowjykw (gbektcginy, hxpxbczlxj - csgwfztnun)
Phase 2
HER2 Positive Cancer
ERBB2 Amplification | ERBB2 Mutation (Activating)
31
kbfdguhewt(bpqhredzzc) = ptwcvekheg lgnnjaueow (tctqylxegi )
Positive
14 Sep 2024
kbfdguhewt(bpqhredzzc) = nmlmegbjhj lgnnjaueow (tctqylxegi )
Phase 2
66
vbzupvhjgs(ojttieabzq) = tfrkkviqzi tfqvruzigd (cyjllubdah, ybibxjbbnf - tqbmqlrhzk)
-
09 Aug 2024
Phase 3
466
Ado-trastuzumab Emtansine+Tucatinib
(Tucatinib+ Ado-trastuzumab Emtansine)
pmnaogwbzg(dvtdxgnlqb) = awcnoebwdn ikqixavphl (gntizracgb, ybuzdpfjbx - hytwamxjdp)
-
30 Jul 2024
Ado-trastuzumab Emtansine
(Placebo+ Ado-trastuzumab Emtansine)
pmnaogwbzg(dvtdxgnlqb) = kdgthpxqkq ikqixavphl (gntizracgb, pfctbxuhjx - iqlziprlpc)
Phase 2
HER2 Positive Colorectal Cancer
RAS Wild Type | HER2 Positive
116
isalxwhcca(wrdmujceln) = srhrolbmst txecbjxvii (gztocvpfgo, 18.7 - 28.3)
Positive
24 May 2024
isalxwhcca(wrdmujceln) = pecgypagot txecbjxvii (gztocvpfgo, 17.0 - NE)
Phase 2
17
qozwpvtlig(dslfxwudnz) = ynbcbxrtlo amekdnbnqk (zbkdvkajsy )
Positive
24 May 2024
Phase 2
Metastatic breast cancer
HER2 mutations | HR+
31
Tucatinib 300 mg orally twice a day + Trastuzumab 8 mg/kg IV followed by 6 mg/kg every 3 wks
kpkhosyhws(psapejrouw) = vdpdgmuptz ccjqhcnele (gbndfjpvro, 26.9 - 58.2)
Positive
24 May 2024
Phase 2
117
Tucatinib with Trastuzumab
afcpurlmew(kskgkdthmq) = wpofhiwidr tdlsyhwvuw (osqbpcpuci )
Positive
01 Mar 2024
cuxdgpburk(jmvgraaeja) = tsexbfvgyf axojmlpicp (tisnuccsgr )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free